Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical ...
Closed, agency-only AI platforms that cannot integrate into enterprise ecosystems face vendor-lock risk and likely attrition ...
PE: Can broad LLMs and smaller, focused LLMs coexist? Rusher: I think they’ll coalesce. It’s already happening where there’s very specific versions of certain LLMs for pharmaceutical research. They ...
Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence. Clinical trials continue to ...
A growing cohort without protective immunity, combined with measles’ high basic transmissibility, enables rapid propagation ...
How are the Rare Disease Evidence Principles (RDEP) reshaping evidentiary expectations? Laksheeta Johari: This is a very ...
However, in the glass box approach, the raw and timestamped data (such as physiological signals like ECG, temperature, or ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Sentynl, a subsidiary of Zydus Lifesciences, entered into a licensing agreement with PRG S&T for Progerinin (SLC-D011), an ...
War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...
Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results